Use of Leukocyte-rich and Platelet-rich Fibrin (L-PRF) Adjunct to Surgical Debridement in the Treatment of Stage 2 and 3 Medication-Related Osteonecrosis of the Jaw

Basit Öğe Kaydı
dc.authoridYalcin, Gul Merve/0000-0002-7438-5834
dc.contributor.authorYalcin-Ulker, Gul Merve
dc.contributor.authorDuygu, Gonca
dc.contributor.authorTanan, Gamze
dc.contributor.authorCakir, Merve
dc.contributor.authorMeral, Deniz Gokce
dc.date.accessioned2024-10-29T17:58:41Z
dc.date.available2024-10-29T17:58:41Z
dc.date.issued2023
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractMedication-related osteonecrosis of the jaw (MRONJ) is characterized by exposed necrotic bone persisting for more than 8 weeks in the maxillofacial region in patients using antiresorptive or antiangiogenetic drugs for several treatment options like bone metastasis or osteoporosis. There are several treatment options studied in scientific literature, and one of them with promising results is using platelet concentrates adjunct to surgical therapy. The aim of this study is to examine the therapeutic effect of leukocyte and platelet-rich fibrin (L-PRF) on patients with MRONJ. This 2-centered study investigated patients referred to oral and maxillofacial surgery departments of 2 university clinics between the years 2014 and 2020 with the diagnosis of MRONJ. Demographic data, the indication of the drug usage, drug type, duration, administration route, and systemic comorbidities of the patients were recorded. L-PRF was applied to 20 osteonecrotic lesions of 19 patients following surgical debridement. The male/female ratio was 5/14. Except 1 of the patients, all of the indications of medication were neoplasia-related. The mean follow-up period of patients was 27.9 & PLUSMN;9.2 months. Most common antirezorptive drug was zoledronate (84.2%). Complete resolution was observed in 16 necrosis sites (80%). It could be concluded that the use of L-PRF may represent an important adjunct in the surgical management of MRONJ.
dc.identifier.doi10.1097/SCS.0000000000009161
dc.identifier.endpage1044
dc.identifier.issn1049-2275
dc.identifier.issn1536-3732
dc.identifier.issue3en_US
dc.identifier.pmid36627754
dc.identifier.scopus2-s2.0-85159292957
dc.identifier.scopusqualityQ2
dc.identifier.startpage1039
dc.identifier.urihttps://doi.org/10.1097/SCS.0000000000009161
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14451
dc.identifier.volume34
dc.identifier.wosWOS:001012652600091
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofJournal of Craniofacial Surgery
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectbisphosphonate
dc.subjectdenosumab
dc.subjectL-PRF
dc.subjectMRONJ
dc.subjectosteonecrosis
dc.subjectautologous platelet concentrates
dc.subjectsurgical debridement
dc.titleUse of Leukocyte-rich and Platelet-rich Fibrin (L-PRF) Adjunct to Surgical Debridement in the Treatment of Stage 2 and 3 Medication-Related Osteonecrosis of the Jaw
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu